Oshi, M.; Newman, S.; Murthy, V.; Tokumaru, Y.; Yan, L.; Matsuyama, R.; Endo, I.; Takabe, K.
ITPKC as a Prognostic and Predictive Biomarker of Neoadjuvant Chemotherapy for Triple Negative Breast Cancer. Cancers 2020, 12, 2758.
https://doi.org/10.3390/cancers12102758
AMA Style
Oshi M, Newman S, Murthy V, Tokumaru Y, Yan L, Matsuyama R, Endo I, Takabe K.
ITPKC as a Prognostic and Predictive Biomarker of Neoadjuvant Chemotherapy for Triple Negative Breast Cancer. Cancers. 2020; 12(10):2758.
https://doi.org/10.3390/cancers12102758
Chicago/Turabian Style
Oshi, Masanori, Stephanie Newman, Vijayashree Murthy, Yoshihisa Tokumaru, Li Yan, Ryusei Matsuyama, Itaru Endo, and Kazuaki Takabe.
2020. "ITPKC as a Prognostic and Predictive Biomarker of Neoadjuvant Chemotherapy for Triple Negative Breast Cancer" Cancers 12, no. 10: 2758.
https://doi.org/10.3390/cancers12102758
APA Style
Oshi, M., Newman, S., Murthy, V., Tokumaru, Y., Yan, L., Matsuyama, R., Endo, I., & Takabe, K.
(2020). ITPKC as a Prognostic and Predictive Biomarker of Neoadjuvant Chemotherapy for Triple Negative Breast Cancer. Cancers, 12(10), 2758.
https://doi.org/10.3390/cancers12102758